Correia et al., 2023 - Google Patents
Inhibition of BMP2 and BMP4 represses Barrett's esophagus while enhancing the regeneration of squamous epithelium in preclinical modelsCorreia et al., 2023
View HTML- Document ID
- 7108673475177074717
- Author
- Correia A
- Straub D
- Read M
- Hoefnagel S
- Romero-Pinedo S
- Abadía-Molina A
- Clemons N
- Wang K
- Calpe S
- Phillips W
- Krishnadath K
- Publication year
- Publication venue
- Cellular and Molecular Gastroenterology and Hepatology
External Links
Snippet
Background & Aims Barrett's esophagus is considered to be a metaplastic lesion that predisposes for esophageal adenocarcinoma. Development of Barrett's esophagus is considered to be driven by sonic hedgehog mediated bone morphogenetic protein (BMP) …
- 201000011497 Barrett's esophagus 0 title abstract description 17
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Correia et al. | Inhibition of BMP2 and BMP4 represses Barrett’s esophagus while enhancing the regeneration of squamous epithelium in preclinical models | |
| Wang et al. | Aberrant epithelial–mesenchymal Hedgehog signaling characterizes Barrett's metaplasia | |
| Waghray et al. | Interleukin-1β promotes gastric atrophy through suppression of Sonic Hedgehog | |
| Pelczar et al. | Inactivation of Patched1 in mice leads to development of gastrointestinal stromal-like tumors that express Pdgfrα but not kit | |
| ES2673209T3 (en) | Colorectal Cancer Treatment Procedures | |
| CA3053392A1 (en) | Antifibrotic activity of cd47 blockade | |
| Wnuk et al. | Neuropilin1 regulates glomerular function and basement membrane composition through pericytes in the mouse kidney | |
| Koga et al. | Transanal delivery of angiotensin converting enzyme inhibitor prevents colonic fibrosis in a mouse colitis model: development of a unique mode of treatment | |
| Yang et al. | Histone demethylase KDM1A promotes hepatic steatosis and inflammation by increasing chromatin accessibility in NAFLD | |
| Li et al. | Phenotypic changes of interstitial cells of Cajal after intestinal obstruction in rat model | |
| Rowland et al. | Enterocyte expression of epidermal growth factor receptor is not required for intestinal adaptation in response to massive small bowel resection | |
| Ou et al. | Epithelial NELF guards intestinal barrier function to ameliorate colitis by maintaining junctional integrity | |
| CN110575540B (en) | Use of PDGF inhibitor for preparing medicine for treating intestinal inflammatory diseases | |
| CN102552935B (en) | Use of hepatocyte nuclear factor-1alpha in treatment of chronic liver disease | |
| CN107982536A (en) | A kind of composition of drug target and application | |
| Saxena et al. | Anti-miRNA therapeutics for uterine fibroids | |
| Hao et al. | Upregulated Tβ4 expression in inflammatory bowel disease impairs the intestinal mucus barrier by inhibiting autophagy in mice | |
| Tecos et al. | Distal small bowel resection yields enhanced intestinal and colonic adaptation | |
| McMellen et al. | Epidermal growth factor receptor signaling modulates chemokine (CXC) ligand 5 expression and is associated with villus angiogenesis after small bowel resection | |
| Yue et al. | IsoalloLCA-intervened regulatory T cell exosomes alleviate inflammatory bowel disease by inhibiting NF-κB-associated inflammation in intestinal epithelial cells | |
| US20210060044A1 (en) | Methods for treating bladder cancer by activation of hedgehog signaling using a methylation inhibitor | |
| Cao et al. | Vegfr3 activation of Pkd2l1+ CSF-cNs triggers the neural stem cell response in spinal cord injury | |
| Bai et al. | Daidzein alleviates CCl 4-and BDL-induced liver fibrosis via suppressing the integrin alphaVbeta1/YAP signaling | |
| Ji et al. | PIM-1 exacerbates sepsis-associated encephalopathy via promoting microglia NLRP3 inflammasome activation | |
| Amit et al. | Use of preclinical models to assess the therapeutic potential of new drug candidates for bladder cancer |